Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) announced its quarterly earnings results on Sunday. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05), MarketWatch Earnings reports. Aurinia Pharmaceuticals had a negative net margin of 173,992.23% and a negative return on equity of 36.98%.
NASDAQ:AUPH opened at $13.40 on Monday. Aurinia Pharmaceuticals has a 52 week low of $4.93 and a 52 week high of $21.93. The firm has a 50 day moving average of $14.91 and a 200 day moving average of $15.16. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -9.12 and a beta of 1.10.
AUPH has been the topic of a number of research reports. BidaskClub downgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, November 11th. Royal Bank of Canada reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a report on Thursday, August 13th. ValuEngine upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, August 3rd. Bloom Burton cut shares of Aurinia Pharmaceuticals from a “buy” rating to an “accumulate” rating in a research report on Tuesday, November 3rd. Finally, HC Wainwright lowered their price objective on shares of Aurinia Pharmaceuticals from $34.00 to $28.00 and set a “buy” rating for the company in a research report on Tuesday, November 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $22.75.
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
See Also: Buy-Side Analysts
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.